News

News Back to resource centre 26 October 2021 Cambridge Cognition wins contract for a pivotal schizophrenia trial Cambridge Cognition, which develops and markets digital solutions to assess brain health, is pleased to announce that it has secured a contract for a further sizeable schizophrenia trial with an existing customer.Cambridge Cognition has been selected again to provide its proprietary gold standard

News Back to resource centre 6 August 2021 Cambridge Cognition: COVID-19 Update We would like to update you on the steps Cambridge Cognition is taking to ensure business continuity for all our customers as the widespread impact of COVID-19 (coronavirus) continues to affect so many globally.This is an unprecedented time for everyone and the situation is continuing to develop. We

News Back to resource centre 1 July 2021 Spin-out of Monument Therapeutics Cambridge Cognition is pleased to announce the completion of the spin-out of Monument Therapeutics, a drug development company applying digital phenotyping to central nervous system (“CNS”) disorders.Cambridge Cognition has been incubating Monument Therapeutics since 2018, with early-stage research supported by two Innovate UK grants. Monument Therapeutics applies a novel drug development

News Back to resource centre 28 June 2021 New £2.2 million contract for at-home cognitive testing in a virtual clinical trial Cambridge Cognition has been selected as the cognitive assessment partner for a large at-home study. The contract is valued at £2.2 million with revenue expected to be recognised by the Company over three years beginning in H2 2021.This is

News Back to resource centre 24 May 2019 NHS Bedfordshire CCG rolls out CANTAB Mobile to 50 practices following successful pilot study We’re pleased to announce that NHS Bedfordshire Clinical Commissioning Group (CCG) is introducing our iPad-based memory assessment tool into 50 general practices.We’re pleased to announce that NHS Bedfordshire Clinical Commissioning Group (CCG) is introducing CANTAB Mobile, our iPad-based

News Back to resource centre 16 March 2017 CANTAB assessments used in EBBINGHAUS cognitive function trial for Amgen’s evolocumab Cambridge Cognition today reports its involvement in Amgen’s EBBINGHAUS study with full results being presented at the American College of Cardiology Annual Scientific Session on 18 March 2017.Cambridge Cognition reports its involvement in Amgen’s EBBINGHAUS study with full results being presented at the American College of Cardiology Annual Scientific Session on

News Back to resource centre 25 January 2017 CANTAB Mobile awarded FDA clearance Cambridge Cognition today announces it has received 510(k) clearance from the U.S. Food and Drug Administration (‘FDA’) to market its CANTAB Mobile product as a medical device in the U.S.Cambridge Cognition today announces it has received 510(k) clearance from the U.S. Food and Drug Administration (‘FDA’) to market CANTAB Mobile as a medical device in the U.S.CANTAB

News Back to resource centre 12 January 2017 Autifony Therapeutics Continues Evaluation of AUT00206 for the Treatment of Schizophrenia Autifony Therapeutics recently presented a poster at the American College of Neuropsychopharmacology following their first human Phase I study in healthy male volunteers to investigate a novel treatment for the positive, negative and cognitive symptoms of schizophrenia.Autifony Therapeutics recently presented a

News Back to resource centre 15 July 2016 First major policy initiative announced from Money and Mental Health Institute On Wednesday 13th July, colleagues from Cambridge Cognition were invited to the House of Commons for the launch of the Money and Mental Health Policy Institute’s first major policy initiative, In Control. On Wednesday 13th July, colleagues from Cambridge Cognition were invited to

News Back to resource centre 20 October 2015 CIPD Annual Conference 2015 Cantab Corporate Health will be demonstrating products and services for managing cognitive wellbeing at the CIPD Annual Conference and Exhibition 2015.Cantab Corporate Health will be demonstrating products and services for managing cognitive wellbeing at the CIPD Annual Conference and Exhibition 2015. The two-day annual event is the meeting